Drugs / Immunotherapy
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02539017 | Nov 2015 → Sep 2017 | triple-negative breast carcinoma | First Affiliated Hospital Xi'an Jiaotong University | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Immunotherapy | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02539017 ↗ |
| Modality | Cell therapy | “Immunotherapy with double dendritic cell (DC)and cytokine-induced killer (CIK) cell” NCT02539017 ↗ |